IP Library Granted Patent US 9,187,552
Granted Patent B2
US 9,187,552 · App. 13/699,213 · Granted Nov 17, 2015

Method for preparing antibodies having improved properties

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,187,552
App. No.
13/699,213
Granted
Nov 17, 2015
Kind
B2
Abstract

The present invention is directed to methods and compositions for the production of Fc-containing polypeptides having improved properties and comprising mutations at positions 243 and 264 of the Fc region.

Claims (13)

1. An Fc-containing polypeptide comprising the amino acid sequence of SEQ ID NO: 18, wherein said SEQ ID NO:18 comprises mutations at amino acid positions 243 and 264 of the Fc region, wherein the mutations are F243A and V264A, wherein the numbering is according to the EU index as in Kabat, and wherein the Fc-containing polypeptide is an antibody or antibody fragment comprising sialylated N-glycans.

2. The Fc-containing polypeptide of claim 1 , wherein the sialic acid residues in the sialylated N-glycans are attached via α-2,6 linkages.

3. The Fc-containing polypeptide of claim 1 or 2 , wherein the Fc-containing polypeptide has one or more of the following properties when compared to a parent Fc-containing polypeptide:

a) reduced effector function,

b) increased anti-inflammatory properties,

c) increased sialylation,

d) increased bioavailability when administered parenterally, and

e) reduced binding to FcγRI, FcγRIIa, FcγRIIb and FcγRIIIa.

4. The Fc-containing polypeptide of claim 1 , wherein at least 70 mole % of the N-glycans in the Fc-containing polypeptide have a structure selected from the group consisting of SA(1-4)Gal(1-4)GlcNAc((2-4)Man3GlcNAc2.

5. The Fc-containing polypeptide of claim 1 , wherein at least 90 mole % of the N-glycans in the Fc-containing polypeptide have a structure selected from the group consisting of SA(1-4)Gal(1-4)GlcNAc((2-4)Man3GlcNAc2.

6. The Fc-containing polypeptide of claim 1 , wherein at least 66 mole % of the N-glycans in the Fc-containing polypeptide have a NANA2Gal2GlcNAc2Man3GlcNAc2 structure.

7. The Fc-containing polypeptide of claim 1 , wherein at least 90 mole % of the N-glycans in the Fc-containing polypeptide have a structure selected from the group consisting of SA(1-4)Gal(1-4)GlcNAc((2-4)Man3GlcNAc2.

8. The Fc-containing polypeptide of claim 1 , wherein at least 66 mole % of the N-glycans in the Fc-containing polypeptide have a NANA2Gal2GlcNAc2Man3GlcNAc2 structure.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 2, 2019
From: STADHEIM, TERRANCE A.; ZHA, DONGXING; LIU, LIMING
To: MERCK SHARP & DOHME CORP.
Reel/Frame 047882/0825 →